| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
The aim of this study is to elucidate the mechanism of EMT and EndoMT in tissue remolding and fibrosis of rheumatic diseases and to develop a new treatment strategy for rheumatic diseases.
We conducted immune-staining of skin, lung and kidney tissue from rheumatic disease including rheumatoid arthritis, systemic sclerosis and vasculitis. As a result, a hyperplasia of myofibroblast was observed at the site of prominent proression of tissue fibrlsis and vascular reumodeling due to endothelial dell proliferation. Immuno-staining revealed both the myoblast and endothelial cells express Wnt10A, suggesting signaling through Wnt10A might involvement in irreversible remodeling in rheumatic diseases. These provocative findings suggest that the inhibition of EndMT/EMT may be a promising target for clinical therapeutic translation in settings such as tissue remodelilng which cause of irreversible organ damage in rheumatic diseases.
|
